After eight weeks of treatment with idelalisib, deuterium labeling data showed cessation of proliferation of the sIgMhi subpopulation, as expected from reports that CLL cells expressing high levels of sIgM (the main determinant of BCR signaling) are most sensitive to BCR inhibition [13, 20]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.